Posaconazole IV solution + Posaconazole powder for oral suspension
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neutropenia
Conditions
Neutropenia
Trial Timeline
Sep 7, 2015 → Sep 3, 2018
NCT ID
NCT02452034About Posaconazole IV solution + Posaconazole powder for oral suspension
Posaconazole IV solution + Posaconazole powder for oral suspension is a phase 1 stage product being developed by Merck for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02452034. Target conditions include Neutropenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02452034 | Phase 1 | Completed |
Competing Products
20 competing products in Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 85 |
| pegfilgrastim | Kyowa Kirin | Phase 2 | 52 |
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| caspofungin acetate + Comparator: AmBisome | Merck | Phase 2 | 52 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 85 |
| Ceftolozane-tazobactam IV | Merck | Approved | 85 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 77 |
| pegfilgrastim | Amgen | Phase 3 | 76 |
| Neulasta (pegfilgrastim) | Amgen | Approved | 84 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 84 |
| Filgrastim Hospira (US) + US-approved Neupogen® | Pfizer | Phase 1 | 32 |
| HSP-130 + US-approved Neulasta + EU-approved Neulasta | Pfizer | Phase 1 | 32 |
| linezolid + vancomycin | Pfizer | Phase 3 | 76 |
| Anidulafungin | Pfizer | Phase 1/2 | 40 |
| Nivestim® | Pfizer | Pre-clinical | 22 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 22 |
| Voriconazole | Pfizer | Phase 1/2 | 40 |
| Filgrastim Hospira (US) + U.S.-approved Neupogen® | Pfizer | Phase 1 | 32 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 74 |